Intellect Neurosciences Common Stock Approved for Trading on OTCQB
Marketwired - Wed Apr 15, 7:02AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced that its securities have been designated as trading on the OTCQB marketplace. Intellect has satisfactorily passed the requirements for eligibility, which include up to date reporting to the SEC, a minimum bid price test of one penny and an annual verification and management certification process providing additional information about the company's insiders, advisors and share count. As a result of the designation, among other things, Intellect investors will enjoy greater information availability through news and disclosure posted through the OTC Disclosure & News Service and transparent prices through full-depth of book with Real Time Level 2 quotes.
Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Thu Mar 19, 6:30AM CDT
Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, issued the following Letter to Shareholders from Elliot Maza, Chairman and CEO.